FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending July 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

Issued:  Thursday 2nd July 2009, London UK



GSK further extends its product portfolio in the Middle East and North Africa


GlaxoSmithKline plc (GSK) today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m). The business comprises a portfolio of 13 branded pharmaceuticals with annual sales in 2008 of $11.8m. This purchase is another step forward in GSK's strategy to accelerate growth in emerging markets and signals a strong commitment to provide quality medicines to patients in the Middle East and North Africa. 


This acquisition builds upon GSK's previous purchases of mature branded products in 2008 from BMS in Pakistan and Egypt, which included a high quality manufacturing plant in Giza, Greater Cairo.  BMS will continue to supply the products acquired today until 2011 when it is anticipated that manufacture will transfer to GSK's Giza plant.


GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com


S M Bicknell

Company Secretary


2 July 2009


Enquiries:



UK Media enquiries:

           Philip Thomson

         (020) 8047 5502


           David Outhwaite

         (020) 8047 5502


           Stephen Rea

         (020) 8047 5502




US Media enquiries:

           Nancy Pekarek

         (919) 483 2839


           Mary Anne Rhyne

         (919) 483 2839


           Kevin Colgan

         (919) 483 2839


           Lisa Behrens

         (919) 483 2839




European Analyst/Investor enquiries:

           David Mawdsley

         (020) 8047 5564


           Sally Ferguson

         (020) 8047 5543


           Gary Davies

         (020) 8047 5503




US Analyst/ Investor enquiries:

           Tom Curry

         (215) 751 5419


           Jen Hill Baxter

         (215) 751 7002




Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.



 

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: July 02, 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc